Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands,
TX 77381-1160
United States - Map
Phone: 281-863-3000
Fax: 281-863-8088
Web Site: http://www.lexpharma.com
| Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The companys drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolutions Chemetics platform chemistry technology. The company was founded in 1995 and is headquartered in The Woodlands, Texas. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Arthur T. Sands M.D., Ph.D., 47
Co-Founder, Chief Exec. Officer, Pres |
$
557.00K |
$
603.00K | Dr. Brian P. Zambrowicz Ph.D., 46
Co-Founder, Chief Scientific Officer and Exec. VP |
$
363.00K |
$
192.00K | Mr. Jeffrey L. Wade J.D., 44
Exec. VP, Sec. and Gen. Counsel |
N/A
| N/A | Dr. Alan J. Main Ph.D., 55
Exec. VP of Pharmaceutical Research |
N/A
| N/A | Dr. Robert J. Lefkowitz M.D., 65
Consultant, Director and Member of Corp. Governance Committee |
$
28.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
